Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study

Nick Andrews,1 Julia Stowe,2 Galena Kuyumdzhieva,2 Bersabeh Sile,2 Ivelina Yonova,3,4 Simon de Lusignan,1,4 Mary Ramsay,2 Gayatri Amirthalingam2


ABSTRACT

Objectives To assess the impact of herpes zoster vaccination in the 5 years after introduction for 70- to 79-year-olds in England in September 2013.

Design Population based ecological impact assessment.

Setting Hospitals covering the whole English population for the period 2008 to 2018 and 293 general practices (GP) for the period 2005 to 2018, in England.

Participants Over the period the population contributed 117-5 million person-years for hospitalisation events and 6.96 million person-years for GP events in individuals aged 60 to 89.

Interventions Live attenuated herpes zoster vaccination (Zostavax), first used on 1st September 2013, in 70- and 79-year-olds with continued use in new 70-year-olds and with a staged catch-up of those aged 71 to 78 years in 2013.

Outcome measures Herpes zoster and postherpetic neuralgia (PHN) consultation and hospitalisation rates in age-cohorts according to vaccine eligibility. Incidence rate ratios in age-cohorts eligible for vaccination compared with those non-eligible were calculated by Poisson regression. This was used to estimate prevented cases and, along with vaccine coverage, to estimate vaccine effectiveness.

Results Large and prolonged reductions in herpes zoster and PHN consultations and hospitalisations were observed in the 5 years post-implementation. For example, in 79 year-olds first eligible in 2013, the incidence rate ratio for consultations 5 years later was 0.65 (95% CI: 0.52 to 0.81). Over the whole period an estimated 40% fewer herpes zoster consultations and 140 fewer herpes zoster hospitalisations occurred because of the vaccination programme. These reductions were consistent with effectiveness in the routine cohorts (vaccinated aged 70) of between 37% (for hospitalised zoster) and 75% (for PHN consultations) and, in catch up cohorts (vaccinated aged 78 to 79) of between 49% (for hospitalised PHN) and 66% (for PHN consultations).

Conclusion Given the clear and sustained impact of herpes zoster vaccination over the 5-year period since introduction, optimising vaccination coverage is important to attain maximum benefit.

INTRODUCTION

The herpes zoster (shingles) vaccine Zostavax (Zoster Vaccine Live; Merck & Co, Kenilworth, New Jersey, USA) was introduced in the UK on 1st September 2013 following the recommendation for its use in immunocompetent 70- to 79-year-olds by the UK’s Joint Committee on Vaccination and Immunisation (JCVI).1,2 The aim of the programme is to boost individuals’ pre-existing immunity to varicella zoster virus (VZV) and prevent herpes zoster which is caused by reactivation of latent VZV. Herpes zoster is typically characterised by a unilateral dermatomal vesicular rash which can lead to complications including postherpetic neuralgia (PHN) in which pain persists for weeks, months or years after the skin lesions have healed and the rash has disappeared. The incidence of herpes zoster varies with age and is higher in immunocompromised individuals and older adults.3 Zostavax is a live attenuated...
herpes zoster vaccine containing the same Oka VZV strain as the childhood varicella vaccine (Varivax) but at a higher dose. Single dose efficacy from clinical trials of 38% against shingles and 67% against PHN over a 5-year follow-up has been demonstrated in adults ≥70 years of age with more recent evidence indicating efficacy maintained at about 30% for herpes zoster and PHN up to 8 years after vaccination. The choice of target age group was based on a cost-effectiveness analysis which incorporated the age-specific incidence of herpes zoster and PHN, the decline in vaccine efficacy with age and the estimated duration of vaccine-induced protection.

In the first year of the programme (2013 to 2014), a single dose of vaccine was offered to adults aged 70 (routine cohort) and 79 years (catch up) on 1st September 2013. In the following 4 years further routine and catch-up cohorts were offered the vaccine as outlined in table 1, with the most recent cohorts offered the vaccine as they turned 70 or 78 years of age rather than by age at September 1 of the year.

Evaluation of the vaccine programme 3 years following its introduction demonstrated a clear impact in these target ages on general practice (GP) consultations for herpes zoster and PHN with herpes zoster incidence reducing from about nine to six per 1000 person-years. In addition, vaccine effectiveness in the 3-year period has been demonstrated as 64% (95% CI: 60% to 68%) against GP consultations for herpes zoster and 81% (95% CI: 61% to 91%) for PHN. In this paper, we extend the previous 3-year evaluation to a 5-year period post introduction, which allows a fuller assessment of waning. We also assess impact on hospitalisations for herpes zoster and PHN allowing a more complete evaluation of the reduction in disease burden.

METHODS

Data sources

The Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) is a sentinel primary care network representing over 1% of the English population that is geographically representative of the general population. In March 2019 we obtained data on herpes zoster, PHN and herpes zoster vaccinations for the period from 1st October 2005 to 30th September 2018 for patients aged 60 to 89 years from all 293 practices in the network. We also obtained denominator data for patients registered each month, stratified by age at 1st September 2013, year/month, gender and GP practice. Events were identified using Read codes (coded thesaurus of clinical terms used for recording patient findings and procedures—see online supplementary file 1). For analysis we aggregated these data using the same strata as for the denominator data. Herpes zoster consultations and PHN consultations were dropped if they occur within 12 months of a previous consultation.

Hospital admissions data

For hospital admissions we used Hospital Episode Statistics (HES) Admitted Patient Care, which contains individual level hospital admissions for all at National Health Service hospitals in England. In August 2019, we obtained all Finished Consultant Episodes for the period from 1st October 2008 to 30th September 2018, for patients aged 60 to 89 years with an International Classification of Diseases (ICD) code B022 herpes zoster or with ICD code G330 PHN in any of the patients 20 diagnosis fields of Diseases (ICD) code B022 herpes zoster or with ICD code G330 PHN in any of the patients 20 diagnosis fields on discharge. We required a minimum gap of 12 months between episodes. We calculated age in September before the year they became ill and aggregated data by age and month/year of admission. To obtain denominators we obtained England Office for National Statistics population statistics by year of age for the period 2008 to 2017 and matched these to the appropriate numerator. We then generated the age on 1st September 2013 so that the vaccine eligible cohorts could be allocated.

Statistical analysis

We defined age cohorts according to participants age on 1st September 2013, which allowed us to identify those targeted in each year of the programme as given in table 1. Those becoming eligible by turning 70 or 78 in 2017 had low uptake in 2017 to 2018 and we therefore excluded these cohorts from the impact analysis from 1st October 2017 by treating them as a separate group for this period. We calculated cumulative vaccine uptake from the RCGP data by summing the vaccine uptake within each month from September 2013 to August 2018 for all cohorts.

Table 1: Eligibility for shingles vaccination in England

<table>
<thead>
<tr>
<th>Birth cohort</th>
<th>Age on 1 Sept 2013 (years)</th>
<th>First became eligible</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine cohorts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Sept 1942 – 1 Sept 1943</td>
<td>70</td>
<td>2013–14</td>
</tr>
<tr>
<td>2 Sept 1943 – 1 Sept 1944</td>
<td>69</td>
<td>2014–15</td>
</tr>
<tr>
<td>2 Sept 1944 – 1 Sept 1945</td>
<td>68</td>
<td>2015–16</td>
</tr>
<tr>
<td>2 Sept 1945 – 1 Sept 1946</td>
<td>67</td>
<td>2016–17</td>
</tr>
<tr>
<td>2 Sept 1946 – 1 Sept 1947</td>
<td>66</td>
<td>2017–18</td>
</tr>
<tr>
<td>2 Sept 1947 – 1 Sept 1948</td>
<td>65</td>
<td>2017–18 (when turning 70)</td>
</tr>
<tr>
<td>Catch-up cohorts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Sept 1933 – 1 Sept 1934</td>
<td>79</td>
<td>2013–14</td>
</tr>
<tr>
<td>2 Sept 1934 – 1 Sept 1936</td>
<td>77 to 78</td>
<td>2014–15</td>
</tr>
<tr>
<td>2 Sept 1936 – 1 Sept 1937</td>
<td>76</td>
<td>2015–16</td>
</tr>
<tr>
<td>2 Sept 1937 – 1 Sept 1938</td>
<td>75</td>
<td>2016–17</td>
</tr>
<tr>
<td>2 Sept 1938 – 1 Sept 1939</td>
<td>74</td>
<td>2017–18</td>
</tr>
<tr>
<td>2 Sept 1939 – 1 Sept 1940</td>
<td>73</td>
<td>2017–18 (when turning 78)</td>
</tr>
</tbody>
</table>

Individuals remain eligible until their 80th birthday.
To assess impact of the vaccine programme, we modelled the incidence of GP consultations as well as of hospital admissions according to age (in years), time period (2005 to 2018 for RCGP and 2008 to 2018 for HES) and vaccine eligibility. Vaccine eligibility is the factor that measures impact and we determined this for each incidence strata according to age and period and assigned this as not eligible, first eligible in that year (defined as 1st October to 30th September), and first eligible in 1, 2, 3 and 4 years previously. The reason for starting in October before measuring impact was to allow time for immunity to develop and to take into account low uptake in the September of each year. Individual vaccination status was therefore not used in this impact analysis, just eligibility by birth cohort. For the RCGP data we also assessed gender and region (London, Midlands, north England and south England) but did not include these in the final models as they did not change impact estimates.

We modelled the data using multivariable Poisson regression with an offset for person time. This model measures impact as the relative incidence in the vaccine eligible cohorts compared with unvaccinated cohorts. We investigated trends by age and period as linear, quadratic and cubic effects as well as an interaction effect between age and period, with the simplest model retained if the simplification did not result in more than a three percentage point change in impact estimates, although we retained a linear period effect in all models. To check robustness of impact estimates we fitted a random effects model with GP as the random effect as well as a model with age and period included as factors rather than polynomials.

To predict the expected incidence and number of events in the absence of vaccination we fitted the final model using data from the cohorts who were not eligible for vaccination and used this to extrapolate to the vaccine eligible cohorts. We also used this model to generate figures of observed compared with modelled incidence as well as a table of observed and expected numbers of events along with expected incidence and incidence reduction. We did sample size calculations prior to obtaining data to ensure reductions of 25% could be detected (80% power and 5% significance). We estimated vaccine effectiveness (VE) consistent with impact and coverage by dividing the impact (percentage reduction) by the average cumulative coverage in the period/age cohort assessed. For example, a VE of 60% is consistent with a 30% reduction and 50% coverage. Precision of VE is based on the 95% CIs for impact. We did all analyses in Stata 14.

**Patient and public involvement**

Patients or the public were not involved in the design or planning of the study.

**RESULTS**

**Vaccine uptake**

Uptake based on the 293 practices contributing to the RCGP RSC shows the routine cohorts in the first 4 years of the programme achieving about 60% to 65% uptake in the first year they are targeted and then having further gradual increases to over 75% (figure 1). The figure does show that more recent routine cohorts have achieved lower coverage, for example, by the August at the end of the first year targeted the first routine cohort (age 70 in September 2013 and vaccinated in 2013/2014) had 63% uptake compared with 46% for the fourth routine cohort (age 66 in September 2013 and vaccinated in 2017/2018). The catch-up cohorts achieve 60% to 65% uptake which plateaus as they are no longer eligible once they reach age 80 (figure 2). Uptake in these practices was similar to that reported nationally which was 61.8%.

![Figure 1](http://bmjopen.bmj.com) Cumulative coverage for each routine age cohort throughout 5-year vaccination programme. Cohorts are grouped by age on 1st September 2013.
59.0%, 54.9%, 48.3%, and 49.1%, respectively, for the first 5 years of the programme in the routine cohorts (aged 70, 69, 68, 67, and 66 years in September 2013) and 59.6%, 57.8%, 58.5%, 55.5%, 49.4%, and 50.8%, respectively, for the catch-up cohorts (79, 78, 77, 76, 75, and 74 years in September 2013). 

**Vaccine impact on GP consultations**

From the 293 RCGP practices the number of patients registered aged 60 to 89 years at October 1st each year increased from 447,567 in 2005 to 621,993 in 2018 with an average of 542,039 over the 14 years. These patients contributed a total 6.96 million person-years of data and are described in table 2 to show herpes zoster and PHN events and rates by vaccine eligibility, year and age. The incidence data were then modelled to estimate vaccine impact. Following the fitting process the final model included the variable to measure impact (vaccine eligibility), a log-linear time trend (a 0.2% increase per year, independent of age) and a quadratic age effect, with incidence increasing from 5.9 per 1000 person-years at 60 to a plateau of 10.2 by age 85. No significant interactions were identified. The model with factors for age and period gave similar results, as did the random effects model.

**Figures 3 and 4** show the observed and predicted incidence from the model in the absence of vaccination for herpes zoster and PHN by year (2005/2006 to 2017/2018) for those cohorts aged between 66 years and 81 years as of September 2013. The figures clearly show the impact in the first year each cohort is targeted for vaccination and its persistence in the following years.

Cumulative uptake observed and predicted cases and relative incidence estimates from the fitted models are summarised for herpes zoster (table 3) and PHN (table 4). The tables also show the vaccine effectiveness required to generate the observed reductions, which is approximately 50% to 60% for herpes zoster. The incidence reduction, if applied to the England population translates to approximately 40,500 fewer herpes zoster (including PHN) episodes over the study period. Reductions were greater for PHN (table 4) with a 47% reduction in PHN incidence in the routine cohorts across the first 5 years and a 38% reduction in the catch-up cohorts. This would be equivalent to a reduction in PHN episodes of 0.6 to 0.7 per 1000 person-years consistent with vaccine effectiveness of approximately 75% for routine and 66% for catch-up cohorts. The incidence reduction, if applied to the England population, translates to approximately 8700 fewer PHN episodes over the 5-year study period.

**Vaccine impact on hospitalisations**

A total of 117.5 million person-years of data for those diagnosed with herpes zoster and PHN aged 60 to 89 from October 2008 to September 2018 were included in the analysis of impact. Table 2 shows person-years and herpes zoster/PHN events contributed by cohorts eligible and not eligible for vaccination by year and age group. Modeling the hospitalisation incidence data indicated that the age followed a cubic trend and time-period a quadratic trend. The cubic age term allowed for a small decline in PHN incidence in the oldest ages (>85) following the usual increase with age. The time trend showed increases over the period (table 2). As with GP consultations no significant interactions were identified and the models with factors for age and time effects and with GP random effects gave similar results.

**Figures 5 and 6** show the observed and predicted incidence from the models in the absence of vaccination for herpes zoster and PHN by year (2008/2009 to 2017/2018) for those cohorts aged between 66 years and 81 years as of September 2013. The figures clearly show the impact in the first year each cohort is targeted for vaccination and in all the following years. Observed and predicted
### Table 2: Description of the aggregated RCGP and hospitalised cohort person-years and herpes zoster events according to vaccine eligibility, year and age

<table>
<thead>
<tr>
<th>Factor</th>
<th>Eligible for vaccination</th>
<th>Not eligible for vaccination</th>
<th>Hospitalisations (England)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GP consultations (RCGP RSC)</td>
<td>Hospitalisations (England)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total person-years* (1000s)</td>
<td>Herpes zoster events (rate per 1000 person-years)</td>
<td>PHN events (rate per 1000 person-years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005–06</td>
<td>446</td>
<td>3514 (7.9)</td>
<td>510 (1.1)</td>
</tr>
<tr>
<td>2006–07</td>
<td>463</td>
<td>3738 (8.1)</td>
<td>548 (1.2)</td>
</tr>
<tr>
<td>2007–08</td>
<td>485</td>
<td>3907 (8.1)</td>
<td>562 (1.2)</td>
</tr>
<tr>
<td>2008–09</td>
<td>501</td>
<td>4010 (8.0)</td>
<td>573 (1.1)</td>
</tr>
<tr>
<td>2009–10</td>
<td>516</td>
<td>4187 (8.1)</td>
<td>598 (1.2)</td>
</tr>
<tr>
<td>2010–11</td>
<td>529</td>
<td>4266 (8.1)</td>
<td>595 (1.1)</td>
</tr>
<tr>
<td>2011–12</td>
<td>542</td>
<td>4386 (8.1)</td>
<td>625 (1.2)</td>
</tr>
<tr>
<td>2012–13</td>
<td>556</td>
<td>4586 (8.3)</td>
<td>652 (1.2)</td>
</tr>
<tr>
<td>2013–14</td>
<td>532</td>
<td>4357 (8.2)</td>
<td>621 (1.2)</td>
</tr>
<tr>
<td>2014–15</td>
<td>489</td>
<td>3946 (8.1)</td>
<td>584 (1.2)</td>
</tr>
<tr>
<td>2015–16</td>
<td>462</td>
<td>3536 (7.7)</td>
<td>511 (1.1)</td>
</tr>
<tr>
<td>2016–17</td>
<td>432</td>
<td>3410 (7.9)</td>
<td>478 (1.1)</td>
</tr>
<tr>
<td>2017–18</td>
<td>351</td>
<td>2888 (7.7)</td>
<td>352 (1.0)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60–69†</td>
<td>3415</td>
<td>23 381 (6.8)</td>
<td>2402 (0.7)</td>
</tr>
<tr>
<td>70–73</td>
<td>346</td>
<td>1940 (5.6)</td>
<td>234 (0.7)</td>
</tr>
<tr>
<td>74–77</td>
<td>26</td>
<td>139 (5.4)</td>
<td>14 (0.5)</td>
</tr>
<tr>
<td>78–82</td>
<td>271</td>
<td>1850 (6.8)</td>
<td>321 (1.2)</td>
</tr>
<tr>
<td>83–89†</td>
<td>14</td>
<td>100 (7.0)</td>
<td>15 (1.1)</td>
</tr>
</tbody>
</table>

*Vaccine eligible person-years includes all time from the point that each age-cohort vaccination first became eligible to receive vaccine.
†Age group not eligible for vaccination.

GP, general practice; PHN, postherpetic neuralgia; RCGP, Royal College of General Practitioners; RSC, Research and Surveillance Centre.

Figure 3 Observed GP-consulted herpes zoster incidence and model-predicted incidence in the absence of vaccination by year for each age cohort. Cohorts are grouped by age at 1 September 2013. Each year runs from October 1 of the first year to September 30 of the second. Blue points indicate observed zoster incidence and red points indicate observed incidence in age cohorts eligible for vaccination. Red lines show the model-predicted incidence in the absence of vaccination. Note that ages 71, 72, 80 and 81 are cohorts not eligible in the period. GP, general practice.

Cases and relative incidence estimates from the fitted models are summarised for herpes zoster (table 5) and PHN (table 6). Reduction for herpes zoster incidence were 23% (range: 19 to 27) across the routine cohorts and 29% (range: 26 to 32) across the catch-up cohorts in the 5 years of the programme. These relative reductions translated into incidence reductions of 0.78 per 10 000 for routine and 2.1 per 10 000 for catch-up cohorts and a total of 1840 prevented herpes zoster (including PHN) hospitalisations for the period 2013/2014 to 2017/2018.

Reductions were greater for PHN (table 6) with a 31% reduction in PHN incidence in the routine cohorts across the first 5 years and a 28% reduction in the catch-up cohorts. This would be equivalent to reduction in PHN episodes of 0.27 and 0.55 per 10 000 person-years and gives an estimated number of PHN hospitalisations prevented of 540. Tables 5 and 6 also show the vaccine effectiveness of approximately 37% to 50% for herpes zoster and 50% for PHN, a little lower than that against GP consultations.

DISCUSSION

In this paper, we provide important evidence of the sustained population impact of the herpes zoster vaccination programme on GP consultations for herpes zoster and postherpetic neuralgia, 5 years following its implementation in England. Despite some challenges in programme implementation and accurately identifying eligible individuals for vaccination, our evaluation

Figure 4 Observed GP-consulted postherpetic neuralgia incidence and model-predicted incidence in the absence of vaccination by year for each age cohort. Cohorts are grouped by age at 1 September 2013. Each year runs from October 1 of the first year to September 30 of the second. Blue points indicate observed zoster incidence and red points indicate observed incidence in age cohorts eligible for vaccination. Red lines show the model-predicted incidence in the absence of vaccination. Note that ages 71, 72, 80 and 81 are cohorts not eligible in the period. GP, general practice.

demonstrates the continued impact observed in the first cohorts targeted for vaccination in 2013/2014, indicating that the effectiveness of the vaccine programme has been maintained. This impact is equivalent to approximately 40,500 fewer GP consultations for herpes zoster and herpes zoster-related disease including 8700 fewer PHN consultations in the first 5 years of the national programme. These levels of disease prevention are particularly relevant in the context of a slowly increasing incidence of herpes zoster over time, reflecting changes in population demographics and is similar to trends observed in other countries.18

For the first time, we additionally demonstrate the impact of the vaccine programme on hospital admissions for herpes zoster and PHN with the impact of hospitalised herpes zoster at a rate similar to that observed for GP consultations for herpes zoster. In total, an estimated 1840 fewer herpes zoster hospitalisations including 540 PHN consultations were prevented in the first 5 years of the programme in England. The reduction in GP consultations and hospitalisations will have large cost savings. Using a cost of £75·60 for a non-PHN GP case, £340·00 for a PHN GP case and £2816 for a hospitalised herpes zoster or PHN case gives a total cost saving of over 10·5 million pounds (£75·60×31 800 + £340×8700 + £1840×2816 = £10 543 520) over the first 5 years of the programme. These costs per case are derived from those used in recent cost-effectiveness analysis (Alicia Rosello, personal communication) and the age distribution of the cases in our analysis. The average annual reduction in hospital costs £1·6 million per year ((£340×8700 + £1840×2816)÷5) compares to an estimated cost prior to vaccination for herpes zoster hospitalisation of £13 million per year across all ages.19 These estimates of reduced burden and cost are likely to be conservative because they do not account for any lack of sensitivity in the coded episodes,
Table 3: Impact of routine and catch-up herpes zoster vaccination on GP-diagnosed herpes zoster by time since cohorts were first eligible for vaccination

<table>
<thead>
<tr>
<th>Period</th>
<th>Age on 1 Sept 2013 (age when first eligible for vaccination)</th>
<th>Average cumulative uptake*</th>
<th>Expected events†</th>
<th>Observed events</th>
<th>Incidence rate ratio‡ (95% CI)</th>
<th>Expected incidence per 1000 person-years (95% CI)</th>
<th>Incidence reduction per 1000 person-years (95% CI)</th>
<th>Vaccine effectiveness§ (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Routine cohorts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First year after vaccine eligibility</td>
<td>66–70 years (70–71 years)</td>
<td>47%</td>
<td>1098</td>
<td>851</td>
<td>0.77 (0.72 to 0.83)</td>
<td>8.24</td>
<td>1.87 (1.42 to 2.30)</td>
<td>48% (37% to 59%)</td>
</tr>
<tr>
<td></td>
<td>(70–71 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Second year after vaccine eligibility</td>
<td>67–70 years (70–71 years)</td>
<td>64%</td>
<td>838</td>
<td>509</td>
<td>0.61 (0.55 to 0.66)</td>
<td>8.45</td>
<td>3.33 (2.85 to 3.76)</td>
<td>61% (53% to 69%)</td>
</tr>
<tr>
<td></td>
<td>(70–71 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Third year after vaccine eligibility</td>
<td>68–70 years (70–71 years)</td>
<td>71%</td>
<td>616</td>
<td>378</td>
<td>0.61 (0.55 to 0.68)</td>
<td>8.66</td>
<td>3.36 (2.79 to 3.88)</td>
<td>54% (45% to 63%)</td>
</tr>
<tr>
<td></td>
<td>(70–71 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fourth year after vaccine eligibility</td>
<td>69–70 years (70–71 years)</td>
<td>75%</td>
<td>413</td>
<td>217</td>
<td>0.52 (0.46 to 0.6)</td>
<td>8.86</td>
<td>4.22 (3.55 to 4.80)</td>
<td>63% (53% to 72%)</td>
</tr>
<tr>
<td></td>
<td>(70–71 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fifth year after vaccine eligibility</td>
<td>70 years (70–71 years)</td>
<td>77%</td>
<td>199</td>
<td>124</td>
<td>0.62 (0.52 to 0.74)</td>
<td>9.05</td>
<td>3.42 (2.33 to 4.34)</td>
<td>49% (33% to 62%)</td>
</tr>
<tr>
<td></td>
<td>(70–71 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All years of the programme</td>
<td>66–70 years (70–71 years)</td>
<td>62%</td>
<td>3164</td>
<td>2079</td>
<td>0.66 (0.63 to 0.69)</td>
<td>8.50</td>
<td>2.92 (2.66 to 3.18)</td>
<td>55% (50% to 60%)</td>
</tr>
<tr>
<td></td>
<td>(70–71 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Catch-up cohorts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Second year after vaccine eligibility</td>
<td>75–79 years (78–80 years)</td>
<td>62%</td>
<td>757</td>
<td>481</td>
<td>0.63 (0.58 to 0.69)</td>
<td>9.82</td>
<td>3.60 (3.00 to 4.14)</td>
<td>59% (49% to 68%)</td>
</tr>
<tr>
<td></td>
<td>(78–80 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Third year after vaccine eligibility</td>
<td>77–79 years (78–80 years)</td>
<td>63%</td>
<td>578</td>
<td>397</td>
<td>0.68 (0.62 to 0.76)</td>
<td>9.95</td>
<td>3.14 (2.42 to 3.79)</td>
<td>50% (38% to 60%)</td>
</tr>
<tr>
<td></td>
<td>(78–80 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fourth year after vaccine eligibility</td>
<td>78–79 years (78–80 years)</td>
<td>63%</td>
<td>409</td>
<td>273</td>
<td>0.67 (0.59 to 0.75)</td>
<td>10.07</td>
<td>3.36 (2.51 to 4.13)</td>
<td>53% (40% to 65%)</td>
</tr>
<tr>
<td></td>
<td>(78–80 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fifth year after vaccine eligibility</td>
<td>79 years (79–80 years)</td>
<td>59%</td>
<td>124</td>
<td>81</td>
<td>0.65 (0.52 to 0.81)</td>
<td>10.18</td>
<td>3.54 (1.91 to 4.84)</td>
<td>58% (32% to 80%)</td>
</tr>
<tr>
<td></td>
<td>(79–80 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All years of the programme</td>
<td>74–79 years (78–80 years)</td>
<td>57%</td>
<td>2811</td>
<td>1950</td>
<td>0.69 (0.66 to 0.73)</td>
<td>9.85</td>
<td>3.02 (2.68 to 3.34)</td>
<td>53% (47% to 59%)</td>
</tr>
<tr>
<td></td>
<td>(78–80 years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Calculated by taking the mean of the cumulative uptake values in each month from October to September of the relevant years and cohorts.
†Expected if vaccine not introduced; based on model results for unvaccinated cohorts.
‡Estimated from the Poisson regression model with a log-linear time trend, quadratic age effect and the factor for vaccine eligibility.
§Effectiveness required to generate the observed reduction given the impact and coverage.
GP, general practice.
### Table 4 Impact of routine and catch-up herpes zoster vaccination on GP-diagnosed postherpetic neuralgia by time since cohorts were first eligible for vaccination

<table>
<thead>
<tr>
<th>Period</th>
<th>Age on 1 Sept 2013 (age when first eligible for vaccination)</th>
<th>Average cumulative uptake*</th>
<th>Expected events†</th>
<th>Observed events</th>
<th>Incidence rate ratio‡ (95% CI)</th>
<th>Expected incidence per 1000 person-years</th>
<th>Incidence reduction per 1000 person-years (95% CI)</th>
<th>Vaccine effectiveness§ (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Routine cohorts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First year after vaccine eligibility</td>
<td>66–70 years (70–71 years)</td>
<td>47%</td>
<td>151</td>
<td>103</td>
<td>0.67 (0.55 to 0.82)</td>
<td>1.13</td>
<td>0.37 (0.20 to 0.51)</td>
<td>70% (38% to 95%)</td>
</tr>
<tr>
<td>Second year after vaccine eligibility</td>
<td>67–70 years (70–71 years)</td>
<td>64%</td>
<td>121</td>
<td>52</td>
<td>0.43 (0.32 to 0.56)</td>
<td>1.22</td>
<td>0.70 (0.53 to 0.82)</td>
<td>89% (68% to 100%)</td>
</tr>
<tr>
<td>Third year after vaccine eligibility</td>
<td>68–70 years (70–71 years)</td>
<td>71%</td>
<td>93</td>
<td>46</td>
<td>0.49 (0.37 to 0.66)</td>
<td>1.30</td>
<td>0.66 (0.45 to 0.83)</td>
<td>71% (48% to 89%)</td>
</tr>
<tr>
<td>Fourth year after vaccine eligibility</td>
<td>69–70 years (70–71 years)</td>
<td>75%</td>
<td>65</td>
<td>35</td>
<td>0.53 (0.38 to 0.75)</td>
<td>1.39</td>
<td>0.65 (0.35 to 0.86)</td>
<td>62% (34% to 82%)</td>
</tr>
<tr>
<td>Fifth year after vaccine eligibility</td>
<td>70 years (70–71 years)</td>
<td>77%</td>
<td>32</td>
<td>12</td>
<td>0.37 (0.21 to 0.64)</td>
<td>1.47</td>
<td>0.93 (0.52 to 1.17)</td>
<td>82% (46% to 100%)</td>
</tr>
<tr>
<td>All years of the programme</td>
<td>66–70 years (70–71 years)</td>
<td>62%</td>
<td>461</td>
<td>248</td>
<td>0.53 (0.46 to 0.61)</td>
<td>1.24</td>
<td>0.58 (0.49 to 0.66)</td>
<td>75% (63% to 86%)</td>
</tr>
<tr>
<td><strong>Catch-up cohorts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First year after vaccine eligibility</td>
<td>74–79 years (78–80 years)</td>
<td>48%</td>
<td>174</td>
<td>133</td>
<td>0.76 (0.63 to 0.90)</td>
<td>1.78</td>
<td>0.44 (0.18 to 0.65)</td>
<td>51% (21% to 77%)</td>
</tr>
<tr>
<td>Second year after vaccine eligibility</td>
<td>75–79 years (78–80 years)</td>
<td>62%</td>
<td>143</td>
<td>87</td>
<td>0.60 (0.48 to 0.74)</td>
<td>1.86</td>
<td>0.75 (0.48 to 0.96)</td>
<td>64% (41% to 83%)</td>
</tr>
<tr>
<td>Third year after vaccine eligibility</td>
<td>77–79 years (78–80 years)</td>
<td>63%</td>
<td>112</td>
<td>48</td>
<td>0.42 (0.32 to 0.56)</td>
<td>1.93</td>
<td>1.12 (0.84 to 1.32)</td>
<td>91% (69% to 100%)</td>
</tr>
<tr>
<td>Fourth year after vaccine eligibility</td>
<td>78–79 years (78–80 years)</td>
<td>63%</td>
<td>81</td>
<td>55</td>
<td>0.67 (0.51 to 0.88)</td>
<td>2.00</td>
<td>0.66 (0.25 to 0.98)</td>
<td>53% (20% to 78%)</td>
</tr>
<tr>
<td>Fifth year after vaccine eligibility</td>
<td>79 years (79–80 years)</td>
<td>59%</td>
<td>25</td>
<td>13</td>
<td>0.51 (0.30 to 0.88)</td>
<td>2.06</td>
<td>1.01 (0.24 to 1.45)</td>
<td>82% (20% to 100%)</td>
</tr>
<tr>
<td>All years of the programme</td>
<td>74–79 years (78–80 years)</td>
<td>57%</td>
<td>536</td>
<td>336</td>
<td>0.62 (0.55 to 0.69)</td>
<td>1.88</td>
<td>0.71 (0.59 to 0.84)</td>
<td>66% (54% to 78%)</td>
</tr>
</tbody>
</table>

*Calculated by taking the mean of the cumulative uptake values in each month from October to September of the relevant years and cohorts.
†Expected if vaccine not introduced; based on model results for unvaccinated cohorts.
‡Estimated from the Poisson regression model with a quadratic time trend, quadratic age effect and the factor for vaccine eligibility.
§Effectiveness required to generate the observed reduction given the impact and coverage.
GP, general practice.
which is likely for PHN, and also do not allow for the fact that some individuals will have had repeat episodes with a year of one another as these were excluded to ensure episodes included were independent.

In our evaluation, the vaccine effectiveness against herpes zoster to generate the observed incidence reductions in GP consultations in the first 5 years following vaccination is approximately 50% to 60%. This compares with long-term efficacy estimated from the long-term persistence study of approximately 38% and suggests that the protection from the vaccine does not wane as rapidly in clinical practice compared with the trial settings.\(^4\)\(^5\) In an 8-year follow-up cohort study in the US between 2007 and 2014, VE was 49.1% (95% CI: 47.5 to 50.6) across all follow-up and VE waned from 67.5% during the first year after vaccination to 31.8% (95% CI: 15.1 to 45.2) by year 8.\(^6\)\(^\text{20}\) Our higher estimates may reflect differences in threshold for health seeking behaviour and the fact that milder cases may not present to general practice, although a US cohort study found lower effectiveness in outpatient data with a decline from 38% (95% CI: 37 to 40) within a year of vaccination to 21% (95% CI: 11 to 31) after seven or more years.\(^6\)\(^\text{21}\) That study found higher estimates and less waning for hospitalised zoster (VE 77% (95% CI: 39 to 67) within a year and 55% (95% CI: 39 to 67) at four or more years). Vaccine effectiveness against PHN was notably higher at 75% for routine cohorts and 66% for catch-up cohorts in the first 5 years of the programme in England. This is more closely aligned to the efficacy generated in the clinical trials with long-term efficacy of 67%, as well as post licensure US studies of PHN with VE at about 50% between 4 and 7 years after vaccination.\(^6\)\(^\text{21}\)\(^\text{22}\) This effectiveness is consistent with evidence that the major benefits from this vaccine are through
Figure 6  Observed hospitalised postherpetic neuralgia incidence and model-predicted incidence in the absence of vaccination by year for each age cohort. Cohorts are grouped by age at 1 September 2013. Each year runs from October 1 of the first year to September 30 of the second. Blue points indicate observed zoster incidence and red points indicate observed incidence in age cohorts eligible for vaccination. Red lines show the model-predicted incidence in the absence of vaccination. Note that ages 71, 72, 80 and 81 are cohorts not eligible in the period.

preventing the complications from severe herpes zoster, rather than preventing herpes zoster itself. Our VE estimates are also similar to those estimated through a formal evaluation in the UK using a cohort design based on an alternative primary care data source. In that study VE was 64% (95% CI: 60% to 68%) against incident herpes zoster and 81% (95% CI: 61% to 91%) against PHN, with very similar VE estimates in the routine and catch-up cohorts and with some evidence of waning for the first 3 years of the programme.8 Similar results have also been reported in other primary care effectiveness studies in the UK with VE seen not to vary by age but being lower in those with type 2 diabetes or prior Zoster.23 24 A key strength of this study is the use of a large population-based sentinel primary care data source with robust historical data on consultations which are geographically representative of the country and provide consistent recording over time. In addition, the use of hospital admissions data across the whole of England adds further weight to this evaluation. Despite this, it is important to note however, that in our study, time since first eligibility for vaccination is only an approximate measure of time since vaccination, particularly in the routine cohorts who continue to be eligible. Nevertheless, the continued low levels in the catch-up cohorts are particularly reassuring.

While, the findings from this 5-year evaluation are reassuring it is of concern that there has been a declining trend in vaccine uptake. Efforts to improve uptake have included simplifying the eligibility criteria for vaccination from April 2017 (ie, eligible on 70th and 78th birthday); although there are challenges in accurately monitoring uptake since this change, it is notable that as yet, this does not appear to have translated into a measurable improvement in uptake. To encourage improved uptake RCGP has added feedback to member practices about their vaccine administration compared with the rest of the network as well as about rates of shingles and PHN; these data are also reported as a national observatory and show impact through the lower proportion of herpes zoster and PHN cases vaccinated than the whole eligible population.25 26
### Table 5  Impact of routine and catch-up herpes zoster vaccination on hospitalised herpes zoster by time since cohorts were first eligible for vaccination

<table>
<thead>
<tr>
<th>Period</th>
<th>Age on 1 Sept 2013 (age when first eligible for vaccination)</th>
<th>Average cumulative uptake*</th>
<th>Expected events†</th>
<th>Observed events</th>
<th>Incidence rate ratio‡ (95% CI)</th>
<th>Expected incidence per 10 000 person-years (95% CI)</th>
<th>Incidence reduction per 10 000 person-years (95% CI)</th>
<th>Vaccine effectiveness§ (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Routine cohorts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First year after vaccine eligibility</td>
<td>66–70 years (70–71 years)</td>
<td>47%</td>
<td>823</td>
<td>686</td>
<td>0.83 (0.77 to 0.90)</td>
<td>2.94</td>
<td>0.50 (0.30 to 0.68)</td>
<td>36% (22% to 49%)</td>
</tr>
<tr>
<td>Second year after vaccine eligibility</td>
<td>67–70 years (70–71 years)</td>
<td>64%</td>
<td>658</td>
<td>519</td>
<td>0.78 (0.72 to 0.86)</td>
<td>3.27</td>
<td>0.71 (0.47 to 0.92)</td>
<td>34% (22% to 44%)</td>
</tr>
<tr>
<td>Third year after vaccine eligibility</td>
<td>68–70 years (70–71 years)</td>
<td>71%</td>
<td>538</td>
<td>395</td>
<td>0.73 (0.66 to 0.81)</td>
<td>3.66</td>
<td>0.99 (0.71 to 1.25)</td>
<td>38% (27% to 48%)</td>
</tr>
<tr>
<td>Fourth year after vaccine eligibility</td>
<td>69–70 years (70–71 years)</td>
<td>75%</td>
<td>394</td>
<td>311</td>
<td>0.78 (0.70 to 0.87)</td>
<td>4.10</td>
<td>0.90 (0.51 to 1.25)</td>
<td>29% (17% to 40%)</td>
</tr>
<tr>
<td>Fifth year after vaccine eligibility</td>
<td>70 years (70–71 years)</td>
<td>77%</td>
<td>205</td>
<td>116</td>
<td>0.56 (0.46 to 0.67)</td>
<td>4.61</td>
<td>2.04 (1.52 to 2.47)</td>
<td>57% (43% to 69%)</td>
</tr>
<tr>
<td>All years of the programme</td>
<td>66–70 years (70–71 years)</td>
<td>62%</td>
<td>2619</td>
<td>2027</td>
<td>0.77 (0.73 to 0.81)</td>
<td>3.41</td>
<td>0.78 (0.65 to 0.91)</td>
<td>37% (31% to 43%)</td>
</tr>
<tr>
<td><strong>Catch-up cohorts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First year after vaccine eligibility</td>
<td>74–79 years (78–80 years)</td>
<td>48%</td>
<td>1277</td>
<td>976</td>
<td>0.76 (0.71 to 0.81)</td>
<td>6.26</td>
<td>1.49 (1.16 to 1.79)</td>
<td>50% (39% to 60%)</td>
</tr>
<tr>
<td>Second year after vaccine eligibility</td>
<td>75–79 years (78–80 years)</td>
<td>62%</td>
<td>1136</td>
<td>770</td>
<td>0.67 (0.63 to 0.73)</td>
<td>7.03</td>
<td>2.29 (1.93 to 2.63)</td>
<td>52% (44% to 60%)</td>
</tr>
<tr>
<td>Third year after vaccine eligibility</td>
<td>77–79 years (78–80 years)</td>
<td>63%</td>
<td>961</td>
<td>656</td>
<td>0.68 (0.62 to 0.73)</td>
<td>7.92</td>
<td>2.57 (2.12 to 2.98)</td>
<td>51% (42% to 59%)</td>
</tr>
<tr>
<td>Fourth year after vaccine eligibility</td>
<td>78–79 years (78–80 years)</td>
<td>63%</td>
<td>756</td>
<td>554</td>
<td>0.72 (0.66 to 0.79)</td>
<td>9.00</td>
<td>2.50 (1.90 to 3.05)</td>
<td>44% (34% to 54%)</td>
</tr>
<tr>
<td>Fifth year after vaccine eligibility</td>
<td>79 years (79–80 years)</td>
<td>59%</td>
<td>251</td>
<td>180</td>
<td>0.70 (0.61 to 0.82)</td>
<td>10.17</td>
<td>3.02 (1.86 to 4.01)</td>
<td>50% (31% to 66%)</td>
</tr>
<tr>
<td>All years of the programme</td>
<td>74–79 years (78–80 years)</td>
<td>57%</td>
<td>4382</td>
<td>3136</td>
<td>0.71 (0.68 to 0.74)</td>
<td>7.36</td>
<td>2.10 (1.88 to 2.32)</td>
<td>50% (45% to 55%)</td>
</tr>
</tbody>
</table>

*Calculated by taking the mean of the cumulative uptake values in each month from October to September of the relevant years and cohorts.
†Expected if vaccine not introduced; based on model results for unvaccinated cohorts.
‡Estimated from the Poisson regression model with a quadratic time trend, cubic age effect and the factor for vaccine eligibility.
§Effectiveness required to generate the observed reduction given the impact and coverage.
Table 6  Impact of routine and catch-up herpes zoster vaccination on hospitalised postherpetic neuralgia by time since cohorts were first eligible for vaccination

<table>
<thead>
<tr>
<th>Period</th>
<th>Age on 1 Sept 2013 (age when first eligible for vaccination)</th>
<th>Average cumulative uptake*</th>
<th>Expected events†</th>
<th>Observed events</th>
<th>Incidence rate ratio‡ (95% CI)</th>
<th>Expected incidence per 10 000 person-years (95% CI)</th>
<th>Incidence reduction per 10 000 person-years (95% CI)</th>
<th>Vaccine effectiveness§ (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine cohorts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First year after vaccine eligibility</td>
<td>66–70 years (70–71 years)</td>
<td>47%</td>
<td>204</td>
<td>154</td>
<td>0.75 (0.64 to 0.88)</td>
<td>0.73</td>
<td>0.18 (0.08 to 0.27)</td>
<td>53% (25% to 77%)</td>
</tr>
<tr>
<td>Second year after vaccine eligibility</td>
<td>67–70 years (70–71 years)</td>
<td>64%</td>
<td>170</td>
<td>133</td>
<td>0.78 (0.65 to 0.93)</td>
<td>0.84</td>
<td>0.19 (0.06 to 0.29)</td>
<td>34% (11% to 54%)</td>
</tr>
<tr>
<td>Third year after vaccine eligibility</td>
<td>68–70 years (70–71 years)</td>
<td>71%</td>
<td>143</td>
<td>92</td>
<td>0.64 (0.52 to 0.79)</td>
<td>0.97</td>
<td>0.35 (0.21 to 0.47)</td>
<td>51% (30% to 68%)</td>
</tr>
<tr>
<td>Fourth year after vaccine eligibility</td>
<td>69–70 years (70–71 years)</td>
<td>75%</td>
<td>108</td>
<td>63</td>
<td>0.58 (0.45 to 0.75)</td>
<td>1.12</td>
<td>0.47 (0.28 to 0.62)</td>
<td>56% (34% to 73%)</td>
</tr>
<tr>
<td>Fifth year after vaccine eligibility</td>
<td>70 years (70–71 years)</td>
<td>77%</td>
<td>57</td>
<td>30</td>
<td>0.52 (0.36 to 0.75)</td>
<td>1.28</td>
<td>0.61 (0.32 to 0.82)</td>
<td>62% (32% to 83%)</td>
</tr>
<tr>
<td>All years of the programme</td>
<td>66–70 years (70–71 years)</td>
<td>62%</td>
<td>682</td>
<td>472</td>
<td>0.69 (0.62 to 0.77)</td>
<td>0.89</td>
<td>0.27 (0.21 to 0.33)</td>
<td>50% (38% to 61%)</td>
</tr>
<tr>
<td>Catch-up cohorts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First year after vaccine eligibility</td>
<td>74–79 years (78–80 years)</td>
<td>48%</td>
<td>343</td>
<td>274</td>
<td>0.80 (0.70 to 0.90)</td>
<td>1.68</td>
<td>0.34 (0.16 to 0.5)</td>
<td>42% (20% to 62%)</td>
</tr>
<tr>
<td>Second year after vaccine eligibility</td>
<td>75–79 years (78–80 years)</td>
<td>62%</td>
<td>303</td>
<td>191</td>
<td>0.63 (0.54 to 0.73)</td>
<td>1.88</td>
<td>0.7 (0.51 to 0.86)</td>
<td>60% (44% to 74%)</td>
</tr>
<tr>
<td>Third year after vaccine eligibility</td>
<td>77–79 years (78–80 years)</td>
<td>63%</td>
<td>252</td>
<td>176</td>
<td>0.69 (0.59 to 0.81)</td>
<td>2.08</td>
<td>0.63 (0.39 to 0.84)</td>
<td>48% (30% to 64%)</td>
</tr>
<tr>
<td>Fourth year after vaccine eligibility</td>
<td>78–79 years (78–80 years)</td>
<td>63%</td>
<td>192</td>
<td>141</td>
<td>0.73 (0.61 to 0.87)</td>
<td>2.28</td>
<td>0.62 (0.3 to 0.89)</td>
<td>43% (21% to 62%)</td>
</tr>
<tr>
<td>Fifth year after vaccine eligibility</td>
<td>79 years (79–80 years)</td>
<td>59%</td>
<td>60</td>
<td>38</td>
<td>0.62 (0.45 to 0.86)</td>
<td>2.45</td>
<td>0.93 (0.34 to 1.35)</td>
<td>64% (24% to 93%)</td>
</tr>
<tr>
<td>All years of the programme</td>
<td>74–79 years (78–80 years)</td>
<td>57%</td>
<td>1150</td>
<td>820</td>
<td>0.72 (0.66 to 0.78)</td>
<td>1.93</td>
<td>0.55 (0.43 to 0.66)</td>
<td>49% (38% to 59%)</td>
</tr>
</tbody>
</table>

*Calculated by taking the mean of the cumulative uptake values in each month from October to September of the relevant years and cohorts.
†Expected if vaccine not introduced; based on model results for unvaccinated cohorts.
‡Estimated from the Poisson regression model with a quadratic time trend, cubic age effect, and the factor for vaccine eligibility.
§Effectiveness required to generate the observed reduction given the impact and coverage.
In 2019, the UK JCVI made specific recommendations for the use of a new recombinant subunit vaccine, Shingrix. This vaccine, licensed as a two-dose schedule, administered at 2- to 6-month intervals, has been shown to have efficacy of >90% in older adults with limited waning to 4 years and has been introduced into the US programme in 2018. As a recombinant vaccine, this vaccine is being recommended in the UK, for use in immunocompromised individuals known to be at high risk of herpes zoster and currently unable to benefit from the existing herpes zoster vaccination programme. In addition, Shingrix has been recommended for use in the routine programme for adults aged 60 to 70 years based on a recent cost-effectiveness analysis. However due to the limited availability to meet high global demand, it is currently not known when Shingrix will be available for use in the UK programme.

The findings from this evaluation of the current herpes zoster vaccination programme in England however should provide considerable reassurance to health professionals and patients and serves as a reminder of the significant health benefits conferred to a target population that is both increasing in size and that is particularly affected from the severe consequences of herpes zoster and herpes zoster-related complications.

Twitter Simon de Lusignan @Lusignan_S

Acknowledgements This study was supported by Public Health England. The patients and practices of the RCGP RSC who allow their pseudonymised clinical medical records data to be used for this study. The authors also wish to thank colleagues at the RCGP RSC secure data and analytics hub at University of Surrey. We thank Alicia Rosello for assistance with the costs calculation of hospitalised and GP consulted herpes zoster.

Contributors NA, GA, KY, SdL and MR were all involved in the concept and design of the evaluation of the herpes zoster vaccination programme. IY and SdL were responsible for providing the RCGP data. JS, BS and GK were responsible for extracting the HES data. NA, JS, IY and BS analysed the data. NA drafted the paper and all authors were involved in the revision. All authors approved the final version and agree to be accountable for all aspects of the work. The corresponding author attests that all listed meet authorship criteria and that no others meeting the criteria have been omitted.

Funding This work was supported by Public Health England.

Competing interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: SdL has received University funding for studies of post vaccination adverse events of interest from GSK, and for attitudes to vaccination from Seqirus; and has been a member of Seqirus and Sanofi advisory boards. Public Health England, National Infection Service, Immunisation and Countermeasures Division has provided vaccine manufacturers with post-marketing surveillance reports, which the Marketing Authorisation Holders are required to submit to the UK licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. No data are available. The general practice data were obtained from the Royal College of General Practitioners Research and Surveillance. For the hospital (HES) data this work was carried out under Regulation 3 of The Health Service (Control of Patient Information) (Secretary of State for Health, 2002). Data cannot be made publicly available for ethical and legal reasons, that is, public availability would compromise patient confidentiality as data tables would include aggregated counts with very small numbers.

REFERENCES


27 Joint Committee on Vaccination and Immunisation. Minute of the meeting held on 06 February 2019. Available: https://app.box.com/s/iddfb4ppwkmtusir2tc/file/424913874479